Cilta-cel’s Japanese BLA Submission Anticipated for H2 2021; CARTITUDE-1 and CARTITUDE-2 Clinical Updates Expected in 2021; No Major Updates for Precision BioSciences; Legend and Precision Q4 2020 Earnings Call Summaries
On Thursday, March 18, Legend held their Q4 2020 earnings presentation (press release / presentation), highlighting the anticipated BLA submission of cilta-cel in Japan, while providing further details on cilta-cel’s rolling submission in the US. Furthermore, Precision BioSciences released their Q4 2020 results (press release), however no major clinical or regulatory updates were provided. Below, Celltelligence provides insights on how cilta-cel’s expansion within Asia could become an important revenue source for JNJ / Legend in the long term.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.